Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has announced the completion of Phase 1 clinical studies for its proprietary therapy, LUCID-MS, designed to treat multiple sclerosis (MS) by targeting demyelination and providing neuroprotection. The company reported that the therapy demonstrated a favorable safety profile and was generally well tolerated among healthy volunteers. This milestone comes as Quantum BioPharma also submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) in April 2026, advancing the program toward clinical development in MS patients.
Multiple sclerosis remains one of the most challenging neurological diseases, affecting more than 2.8 million people worldwide and approximately 1 million in the United States. The disease is a chronic autoimmune and neurodegenerative condition in which the immune system attacks myelin, the protective sheath surrounding nerve fibers in the brain and spinal cord. As myelin deteriorates, communication between nerves becomes disrupted, leading to symptoms that can include loss of mobility and bodily control. Despite the availability of numerous immune-modulating therapies, many patients continue to experience worsening disability because current treatments often focus on reducing inflammation and relapse frequency but may not adequately address the underlying neurodegeneration and myelin damage that drive long-term disease progression.
Quantum BioPharma’s LUCID-MS program is built around this unmet need for MS therapies capable of directly protecting or restoring myelin integrity. The company believes that LUCID-MS, a patented therapeutic candidate, could offer a new approach to addressing the loss of mobility and function experienced by MS patients. The completion of Phase 1 studies and the IND submission represent significant steps toward bringing this potential treatment to clinical trials in patients.
The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM.
This development is important for the MS community, as it highlights a potential shift toward therapies that not only manage symptoms but also aim to repair the underlying damage to the nervous system. If successful in future trials, LUCID-MS could offer new hope for the millions of people living with MS who currently face limited options for halting or reversing disease progression. The favorable safety profile from Phase 1 studies is an encouraging sign, but further research will be necessary to determine efficacy and long-term outcomes in patients.
